NCT03617328: A trial that was reported late by Craig L Slingluff, Jr
This trial has reported, although it was 187 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03617328 |
|---|---|
| Title | Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 13, 2018 |
| Completion date | Jan. 19, 2024 |
| Required reporting date | Jan. 18, 2025, midnight |
| Actual reporting date | July 25, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 187 |